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Abstract
Foot-and-mouth disease (FMD) remains one of the most economically important infectious
diseases of production animals globally. Vaccination can successfully control this disease,
however, current vaccines are imperfect. They are made using chemically inactivated FMD
virus (FMDV) that is produced in large-scale mammalian cell culture under high contain-
ment conditions. Here, we have expressed the FMDV capsid protein precursor (P1-2A) of
strain O1 Manisa alone or with the FMDV 3C protease (3Cpro) using a “single cycle” pack-
aged alphavirus self-replicating RNA based on Semliki Forest virus (SFV). When the FMDV
P1-2A was expressed with 3Cpro then processing of the FMDV capsid precursor protein is
observed within cells and the proteins assemble into empty capsid particles. The products
interact with anti-FMDV antibodies in an ELISA and bind to the integrin αvβ6 (a cellular
receptor for FMDV). In cattle vaccinated with these rSFV-FMDV vectors alone, anti-FMDV
antibodies were elicited but the immune response was insufficient to give protection against
FMDV challenge. However, the prior vaccination with these vectors resulted in a much
stronger immune response against FMDV post-challenge and the viremia observed was
decreased in level and duration. In subsequent experiments, cattle were sequentially vacci-
nated with a rSFV-FMDV followed by recombinant FMDV empty capsid particles, or vice
versa, prior to challenge. Animals given a primary vaccination with the rSFV-FMDV vector
and then boosted with FMDV empty capsids showed a strong anti-FMDV antibody
response prior to challenge, they were protected against disease and no FMDV RNA was
detected in their sera post-challenge. Initial inoculation with empty capsids followed by the
rSFV-FMDV was much less effective at combating the FMDV challenge and a large post-
challenge boost to the level of anti-FMDV antibodies was observed. This prime-boost
system, using reagents that can be generated outside of high-containment facilities, offers
significant advantages to achieve control of FMD by vaccination.
PLOS ONE | DOI:10.1371/journal.pone.0157435 June 13, 2016 1 / 23
a11111
OPEN ACCESS
Citation: Gullberg M, Lohse L, Bøtner A, McInerney
GM, Burman A, Jackson T, et al. (2016) A Prime-
Boost Vaccination Strategy in Cattle to Prevent Foot-
and-Mouth Disease Using a “Single-Cycle”
Alphavirus Vector and Empty Capsid Particles. PLoS
ONE 11(6): e0157435. doi:10.1371/journal.
pone.0157435
Editor: Jagadeesh Bayry, Institut National de la
Santé et de la Recherche Médicale (INSERM),
FRANCE
Received: April 5, 2016
Accepted: May 31, 2016
Published: June 13, 2016
Copyright: © 2016 Gullberg et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by the Danish
Council for Independent Research | Technology and
Production Sciences (FTP grant 09-070549) to CP
and GJB, plus Defra (UK) project number SE1127 to
TJ and internal funding from DTU National Veterinary
Institute to GJB.
Introduction
Foot-and-mouth disease (FMD) remains one of the most feared virus infections of farm ani-
mals. The virus can infect cattle, pigs, sheep and goats plus about 70 wildlife species. The dis-
ease continues to affect over 100 countries and has a huge economic impact globally which has
been estimated at about US$10,000,000,000 annually [1]. Indeed outbreaks within individual
countries, that have highly developed agriculture, can also have economic consequences of this
severity; for example, the epizootic in the UK, in 2001, affected more than 2000 farms and
resulted in the slaughter of several million animals [2].
The disease is caused by infection with foot-and-mouth disease virus (FMDV); this is the
prototypic member of the Aphthovirus genus within the family Picornaviridae. Like other
picornaviruses, FMDV has a single-stranded, positive sense, RNA genome that is enclosed
within a protein shell comprised of 60 copies of 4 different structural proteins, VP1, VP2, VP3
and VP4. Only VP1-VP3 are surface exposed on the virus particles, whereas the VP4 is internal
[3]. The capsid serves to protect the RNA genome when the virus is outside of the cell. In addi-
tion, the capsid proteins facilitate virus entry (by binding to certain integrin receptors, e.g.
αvβ6) [4,5] and delivery of the genome into the cytoplasm of the cell where translation and rep-
lication of the viral RNA takes place and new virus particles are formed [6]. The surface
exposed capsid proteins are also recognized by the immune system of infected animals and
induce neutralizing antibodies, the key requirement for protection against infection by this
virus (reviewed in [7]).
There are seven different serotypes of FMDV, namely O, A, C, SAT 1, SAT 2, SAT 3 and
Asia-1. Infection by, or vaccination against, one serotype does not confer protection against
other serotypes. Current vaccines against FMD are based on chemically inactivated FMDV,
grown in cell culture, and used with a suitable adjuvant [7,8]. The FMDV antigen is generally
purified to remove the non-structural proteins (NSPs) produced by the virus since the lack of
antibodies to the NSPs can enable vaccinated animals to be distinguished from infected ani-
mals. Current vaccines confer relatively short-term immunity (vaccination is often performed
2–3 times per year in countries where this is permitted) and require maintenance of a cold-
chain. Vaccination against FMDV helped to free Europe from the disease in the 1960’s and
1970’s but currently vaccination against FMDV is not permitted in Europe except in the face of
an outbreak. However, the scale of the FMDV outbreak in the UK in 2001 has encouraged the
search for improved vaccines against this disease [9]. The most successful viral vaccines have
been based on “live” attenuated viruses (e.g. for smallpox, rinderpest and poliovirus) but no
such “live” FMDV vaccine, has been found to be satisfactory.
It is possible to produce FMDV empty capsid particles (which comprise 60 copies of VP0
(uncleaved VP4 and VP2), VP3 and VP1) by expressing the capsid protein precursor P1-2A in
cells along with the FMDV 3C protease (3Cpro) [10,11,12,13]. This viral protease processes the
P1-2A precursor to VP0, VP3 and VP1 (and the 2A peptide) and these proteins “self-assemble”
into particles. The P1-2A precursor is modified on the N-terminal Gly (G) residue by the cellu-
lar myristoylation machinery [14]. This post-translational modification is essential for the
assembly and/or stability of most picornavirus capsids [10,15]. Recombinant empty capsid par-
ticles produced in this way may represent a good alternative to the conventional FMDV vac-
cine since they are non-infectious and can be made outside of high containment facilities and
may also be modified to enhance their stability [11,16,17,18,19]. However, vaccines based on
these empty capsid particles may still be expected to suffer from some of the same shortcom-
ings, (e.g. in terms of duration of immunity), as the current inactivated vaccines.
Infectious vaccines (such as live attenuated viruses or vaccines delivered by modified viral
vectors) are able to produce virus antigens within infected cells and then these can be presented
Prime-Boost Vaccination to Block FMD
PLOSONE | DOI:10.1371/journal.pone.0157435 June 13, 2016 2 / 23
Competing Interests: A patent application has been
filed by GJB, MG and CP concerning parts of the
work described here. This does not alter the authors'
adherence to PLOS ONE policies on sharing data
and materials as described in http://www.PLOSone.
org/static/editorial.action#competing.
on the cell surface to the immune system. The expression of serotype A FMDV capsid proteins
using an infectious adenovirus vector has been described and good protection against challenge
has been achieved in cattle [20]. However, analogous adenoviruses expressing serotype O cap-
sid proteins have been less successful [21]; it is important to note that serotype O FMDV is the
most common globally. High doses of the recombinant adenoviruses are required to induce
protection against FMDV. It may be that these viral vectors, which express the RNA transcripts
from within the nucleus of mammalian cells, are not optimal [9].
Certain cytoplasmic RNA viruses have been modified for use as expression vectors (see
[22]). The alphaviruses, like picornaviruses, have a positive sense RNA genome, however, in
addition to the genomic RNA, alphaviruses also produce a sub-genomic RNA that encodes the
viral structural proteins. This subgenomic RNA is not required for RNA replication and hence
can be modified without impeding this process. Expression vectors based on Semliki Forest
virus (SFV) have been described [22] and derivatives that use a “split helper” system have been
developed [23]. In this system, packaging of the modified SFV genomic RNA transcripts is
achieved by co-expression of two separate helper RNAs encoding the capsid and envelope
structural proteins. Only the modified genomic RNAs, containing a packaging signal, are
incorporated into progeny SFV particles while the mRNAs encoding the capsid and spike pro-
teins are translated to produce the structural proteins. The virus particles made in this way can
infect cells but are unable to generate new infectious progeny; thus only a single round of cell
infection occurs.
In this study, RNA sequences encoding a serotype O FMDV capsid protein precursor (P1-
2A), with the FMDV 3Cpro, have been expressed from recombinant SFV (rSFV) vectors in cells
and FMDV empty capsid particles were produced. Vaccination of cattle with these
rSFV-FMDV vectors primed a strong anti-FMDV immune response that was observed follow-
ing a booster vaccination, with FMDV empty capsid particles. This resulted in a complete
block on FMDV circulation within the animals following virus challenge and the animals were
protected against disease.
Materials and Methods
Plasmid construction
The FMDV cDNA cassettes used in this study, that encode the capsid precursor (P1-2A) alone
or with 3Cpro are shown in Fig 1 and were prepared by standard methods [24]. The split-helper
RNA system for production of single cycle rSFV virus particles was based on the use of the
previously published pSFV3 [25], pSFV-helper-C-S219A and pSFV-helper-S2 vectors [23].
The cDNA sequences corresponding to the O1 Manisa FMDV capsid precursor (in pGEM-
3Z-O-P1-2A) alone or together with a mutant form of 3Cpro, with reduced catalytic activity
(3CC142S from pGEM-3Z-O-P1-2A-3CC142S), or with low level expression of the wt 3C
(IRESgtta3Cwt from pGEM-3Z-O-P1-2A-IRESgtta3Cwt) have been described elsewhere
[13,26]. These three plasmids were digested with EcoRI and XmaI to release the FMDV cDNA
cassettes, and the pSFV3 vector was digested with BglII and XmaI and separately with BglII
and EcoRI (the pSFV3 vector contains three EcoRI sites). The plasmids pSFV3-FMDV-P1-2A,
pSFV3-FMDV-P1-2A-3CC142S and pSFV3-FMDV-P1-2A-mIRES3Cwt (with the serotype O
P1-2A-IRESgtta3Cwt cassette) were made through single-step three-part ligations (between
the different EcoRI/XmaI fragments and the two parts of the backbone vector, i.e. a XmaI/BglII
fragment and a BglII/EcoRI fragment). Plasmids were amplified in Escherichia coli (Top10,
Invitrogen), purified (Midiprep kit, Fermentas) and verified by sequencing.
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In vitro transcription, electroporation and packaging of recombinant
SFV-FMDV RNAs
The methods used to transcribe capped RNAs in vitro, electroporate the RNA into BHK (baby
hamster kidney, ATCC-CCL-10) cells and to produce single-cycle infectious rSFV particles
were performed as previously described [22]. Briefly, the plasmids were linearized by digestion
with SpeI, purified (QIAquick PCR purification kit, Qiagen) and in vitro transcribed using SP6
RNA polymerase (mMessage mMachine kit, Ambion), in 20 μl reactions, as described by the
Fig 1. Schematic representation of the FMDV genome and the rSFV plasmids used in this study. The P1-2A, P1-
2A-3CC142S and P1-2A-mIRES-3C FMDV cDNA cassettes have been described elsewhere [13,26] while the pSFV3
and the split helper plasmids have also been described previously [23]. Positions of relevant restriction enzyme sites
used are shown. Abbreviations: P1-2A: capsid precursor protein; 3C: 3Cpro wild-type or C142Smutant; mIRES: internal
ribosome entry site GTTAmutant; SP6: SP6 promotor; nsP1-P4: SFV non-structural proteins 1–4; PS: packaging signal;
26S: SFV 26S subgenomic promotor; C: SFV capsid; p62, 6K and E1: SFV spike proteins.
doi:10.1371/journal.pone.0157435.g001
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manufacturer. The integrity of the RNA transcripts was analysed using agarose gel electropho-
resis and the transcripts were introduced into BHK cells by electroporation, as described previ-
ously [27,28]. To package the recombinant RNAs into rSFV particles using the two-helper
RNA system, 20 μl of each RNA transcription reaction was used (i.e. a particular rSFV RNA
plus the two separate helper RNA transcripts). The medium containing the rSFV particles was
harvested, following incubation at 33°C, within 48 h post electroporation, after the develop-
ment of cytopathic effect (CPE), and clarified by centrifugation at 40,000xg for 30 min at 4°C.
To concentrate and purify the rSFV-FMDV particles from the medium (when necessary, only
for animal experiments 1 and 2), they were sedimented, by ultracentrifugation, through a 20%
sucrose cushion at 140,000xg for 90 min at 4°C and resuspended in 50 mM Tris-HCl (pH 7.4),
100 mM NaCl and 0.5 mM EDTA. The rescued rSFVs were termed: rSFV-FMDV-P1-2A,
rSFV-FMDV-P1-2A-3CC142S and rSFV-FMDV-P1-2A-mIRES-3C respectively.
Immunofluorescence assays
Titres of the packaged rSFV-FMDV particles (as infectious rSFV-FMDV units/ml) were quan-
tified by immunofluorescence assays essentially as described previously [22]. Briefly, monolay-
ers of BHK cells, grown on glass coverslips in 35 mm wells plates, were infected with 10-fold
dilutions of the harvested rSFV-FMDV particles. After incubation at 37°C for 10 to 16 h, the
cells were fixed, stained and mounted as previously described [29]. In brief, to identify cells
containing FMDV-capsid proteins, the cells were stained using a polyclonal rabbit anti-FMDV
O1Manisa antibody followed by a donkey Alexa-fluor 568-labelled anti-rabbit IgG (A10042,
Life Technologies) and viewed using an epifluorescence microscope.
Infection of cells with rSFV-FMDV particles
BHK, IBRS-2 (porcine kidney, ATCC CRL-1835) and pBTY (primary bovine thyroid, pro-
duced in-house) cells were infected with rSFV-FMDV particles at a multiplicity of infection
(MOI) of 20 infectious units/cell for 1 h, as described previously [22], and incubated at 37°C.
At 10 to 16 h post infection, cell lysates were prepared using 20 mM Tris-HCl (pH 8.0), 125
mMNaCl and 0.5% NP-40, and clarified by centrifugation at 18,000 x g for 10 min at 4°C.
Samples were examined for the presence of FMDV proteins by immunoblotting and enzyme-
linked immunosorbent assays (ELISA) as described below.
Immunoblotting
Immunoblotting was performed according to standard methods as described previously [26].
Briefly, samples were mixed with Laemmli sample buffer (with 25 mM dithiothreitol), sepa-
rated by SDS-PAGE (12.5% or 15% polyacrylamide) and transferred to polyvinylidene difluor-
ide membranes (PVDF, Millipore). These were incubated with primary antibodies specific for
the FMDV capsid proteins (anti-FMDV O1Manisa guinea pig serum), FMDV 2A (ABS31,
Millipore), actin (ab8227, Abcam) or FMDV 3Cpro (anti-FMDV 3C 1G1, kindly provided by E.
Brocchi, Brescia, Italy, as used previously [30]. Immunoreactive proteins were visualized using
appropriate secondary horseradish peroxidase-conjugated antibodies (Dako) and a chemilumi-
nescence detection kit (ECL Prime, Amersham) with a Chemi-Doc XRS system (Bio-Rad).
ELISAs
Serotype-specific FMDV antigen ELISAs (for serotype O) were performed as described previ-
ously [31,32]. The ELISA to detect FMDV antigen binding to the integrin αvβ6 (a cellular
receptor for FMDV) was performed as described [26].
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Sucrose gradient analyses
Cell extracts from rSFV-FMDV infected BHK cells (400 μl of lysate prepared from one 35 mm
well per gradient) were loaded onto 10 to 30% (w/v) sucrose gradients and centrifuged as previ-
ously described [29]. Viral proteins were detected in collected fractions by the serotype-specific
FMDV antigen ELISA (as described above).
Ethics Statement
All animal work was approved and conducted according to the requirements of the Danish
Animal Experiment Inspectorate (Licence nos. 2012-15-2934-00182 and 2012-15-0201-
00173). Susceptible cattle exhibited typical clinical signs of FMD following virus challenge but
all recovered in a few days and none died as a result of this infection. At the termination of the
experiment, all animals were humanely euthanized.
Vaccination and challenge of cattle
In experiment 1, eight cattle of 2–6 months of age were divided into three groups, one group
with two animals (control group 1, animals C1 and C2) and the other two groups with three
animals in each (group 2, animals C3, C4 and C5 and group 3, animals C6, C7 and C8). Group
2 (C3-C5) and group 3 (C6-C8) were vaccinated subcutaneously with 5x108 infectious units of
rSFV-FMDV-P1-2A or rSFV-FMDV-P1-2A-mIRES-3C that express the FMDV P1-2A or
FMDV P1-2A-mIRES-3C cassettes respectively. The control group received injections of PBS.
The procedure used to challenge the cattle has been described elsewhere [33]. Briefly, at post
vaccination day (PVD) 21, the animals were challenged by sub-epithelial injection, in the ton-
gue, with ca. 106 TCID50 (in total, as determined in pBTY cells) of FMDV O UKG 34/2001. All
animals were monitored daily, with measurements of rectal temperature and observation of
clinical signs (drooling and appearance of lesions in the mouth and on the feet). Serum samples
were collected at predetermined times until PVD 30 when the experiment was terminated.
In experiment 2, thirteen calves were divided into 5 groups. The control groups, 1 (C1, C2)
and 2 (C3, C4), each consisted of two cattle while the test groups 3 (C5-C7), 4 (C8-C10) and 5
(C11-C13) each comprised 3 animals. Cattle in groups 3, 4 and 5 each received 7.5 x 108 infec-
tious units of the rSFV-FMDV-P1-2A-mIRES-3C on PVD 0 and then again on PVD 14. Ani-
mals in groups 1 and 3 were inoculated into the tongue with FMDV O UKG 34/2001 (ca. 106
TCID50) on PVD 28. Animals in group 2 (C3-C4, unvaccinated) and group 5 (C11-C13, twice
vaccinated) were kept in close contact with those from group 1 (C1-C2) from one day after
challenge (PVD 29) in one stable while cattle in group 4 (C8-C10) were kept in contact with
the vaccinated and inoculated cattle (C5-C7) in group 3 within another stable. All animals
were monitored daily and blood samples were collected at pre-determined times until day 42
when the experiment was terminated.
In the animal experiment 3, nine calves were divided equally into 3 groups. The control
group 1 (C1-C3) was unvaccinated while the group 2 (C4-C6) was inoculated with
rSFV-FMDV-P1-2A-mIRES-3C (4 x 108 infectious units) on PVD 0 and then boosted on PVD
14 with ca. 10 μg of O1 Manisa empty capsid particles with Montanide ISA 201 VG (Seppic)
mineral oil adjuvant. Group 3 (C7-C9) received the same inoculations but in the opposite
order, thus the animals were inoculated with the O1 Manisa empty capsid particles (in adju-
vant) on PVD 0 and then with the rSFV-FMDV-P1-2A-mIRES-3C on PVD 14. The empty
capsid particles were produced by dual infection of RK13 (rabbit kidney, ATCC CCL-37) cells
with the vaccinia virus vTF7-3 [34], that expresses the T7 RNA polymerase, and another vac-
cinia virus containing a T7-P1-2A-3Cpro O1 Manisa cDNA cassette [35]. The empty capsids
were then purified by sucrose gradient centrifugation essentially as previously described [11].
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All animals were challenged on PVD 28 by needle inoculation into the tongue (as in experi-
ment 1, see above).
The presence of FMDV RNA and anti-FMDV antibodies in the cattle serum samples were
determined by RT-qPCR (targeting the 5'-UTR [36]) and a blocking ELISA [37], respectively.
The level of viral RNA detected in serum samples was converted to the number of genome cop-
ies by reference to a standard curve of reference RNA samples, assayed in parallel, as described
previously [27]. Selected serum samples were titrated in the blocking ELISA, using 2-fold dilu-
tions from an initial 1:5 dilution. The titre is the lowest dilution giving a positive signal.
The presence of neutralising anti-FMDV antibodies in sera was determined using virus neu-
tralization assays (VNTs) with O1 Manisa FMDV (ca. 100 TCID50) in IBRS2 cells, essentially
as described previously [31]. Each serum dilution was assayed in 4 wells and the appearance of
CPE was scored following incubation for 72 hrs. Results were expressed as reciprocal VNT
titres derived from the serum dilution giving 50% neutralization and are plotted as log2 values.
Results
Construction of pSFV-FMDV plasmids
In previous studies [13,26], we have described the three serotype O FMDV cDNA cassettes
indicated in Fig 1. One cassette encodes the FMDV capsid precursor P1-2A (from O1 Manisa)
alone while the P1-2A-3CC142S cassette encodes the FMDV P1-2A linked directly (within a
single open reading frame (ORF)) to a mutant form of the FMDV 3Cpro with much reduced
catalytic activity [38]. The third FMDV cDNA cassette, P1-2A-mIRES-3C, includes two sepa-
rate ORFs for P1-2A and the wt 3Cpro; the expression of the 3Cpro is dependent on a mutant
form of the FMDV IRES element (termed GTTA) that is highly defective (ca. 10% of wt activ-
ity) and therefore only produces a relatively low level of the protease relative to the capsid pre-
cursor. Each of these three cassettes has been introduced into the SFV expression vector called
pSFV3 [23] so that the production of the RNA transcripts containing the FMDV sequences is
dependent on the activity of the SFV 26S sub-genomic promoter (Fig 1).
Expression of FMDV capsid proteins using the SFV two-helper system
Capped RNA transcripts were prepared in vitro, using SP6 RNA polymerase, from pSFV3 and
its 3 derivatives containing the FMDV cDNA cassettes and also from the two helper plasmids
pHelper-CS219A and pHelper-S2 (see Fig 1). The production and integrity of the RNA tran-
scripts was verified by agarose gel electrophoresis and then each rSFV transcript was electropo-
rated into BHK cells in conjunction with the two helper RNAs. Following incubation at 33°C,
CPE was observed and virus harvests were prepared; these were termed rSFV3 (no FMDV
insert), rSFV-FMDV-P1-2A, rSFV-FMDV-P1-2A-3CC142S and rSFV-FMDV-P1-2A-mIRES-
3C. To titrate these virus stocks, known dilutions were used to infect BHK cells and after 16 h the
cells were fixed and stained for the presence of FMDV capsid proteins (data not shown). The
expression of FMDV proteins in BHK cells infected with each of these virus stocks is shown in
Fig 2. As expected, no staining for FMDV proteins was observed in mock or rSFV3-infected cells
(Fig 2A and 2B). In contrast, FMDV proteins were detected from each of the rSFV-FMDVs that
express sub-genomic RNA transcripts including the FMDV sequences (Fig 2C–2E).
Characterization of expressed FMDV capsid proteins
In order to confirm that the expected FMDV proteins were being expressed within cells
infected with the different rSFVs, cell lysates were prepared and analysed by immunoblotting
using antibodies specific for the FMDV capsid proteins, for the FMDV 2A and also for the
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FMDV 3Cpro (Fig 3A). No products were detected by these antibodies in mock or rSFV3
infected cells (lanes 1–2). However, as expected, the rSFV-FMDV-P1-2A expressed the intact
capsid precursor (apparent Mr ca. 90kDa, see lane 3) and processing to the mature capsid pro-
teins (including VP0 and VP1) was observed from the rSFV-FMDVs that also encoded the
FMDV 3Cpro (see lanes 4 and 5; note, the VP3 is not detected by this anti-FMDV antiserum).
Consistent with earlier studies using the vaccinia virus transient expression system [13], pro-
cessing of the VP1/2A junction was incomplete when low levels of the 3Cpro activity were pro-
duced (Fig 3A, lanes 4 and 5); note the presence of VP1-2A, as detected by the anti-2A
antiserum. It appears that processing of the VP1/2A junction is the slowest of the 3Cpro-medi-
ated cleavages within the P1-2A precursor in cells. The 3Cpro itself, could only be detected in
the immunoblot from the rSFV-FMDV-P1-2A-3CC142S virus (Fig 3A, lane 4). Due to the low
level of protease activity of this mutant protein, the expression systems are able to tolerate
higher levels of this protein than wt 3Cpro. However, clearly the level of 3Cpro activity achieved
by the low-level expression of the wild-type protease from the P1-2A-mIRES-3C cassette was
sufficient to achieve efficient processing of the P1-2A (Fig 3A, lane 5).
To determine the antigenicity of the FMDV proteins expressed by the rSFV-FMDV vectors,
samples of the infected cell lysates were also tested in a FMDV serotype specific antigen ELISA.
Fig 2. Expression of FMDV capsid proteins using the SFV split-helper system.Uninfected BHK cells (A)
or cells infected with rSFV (B), rSFV-FMDV-P1-2A (C), rSFV-FMDV-P1-2A-3CC142S (D) or rSFV-FMDV-P1-
2A-mIRES-3C (E), at an MOI of 20, were immunostained at 16 h post infection. FMDV proteins were detected
with an anti-FMDV O1Manisa polyclonal antibody and a secondary antibody labeled with Alexa Fluor 568
(red). The cellular nuclei were visualized with DAPI (blue). Bar, 100 μm. The results shown are representative
of three independent experiments.
doi:10.1371/journal.pone.0157435.g002
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No signal was detected from the mock-infected or control rSFV3 virus infected BHK cells (Fig
3B) but strong signals were observed with each of rSFV-FMDV infected-cell lysates, i.e. includ-
ing both the intact and processed forms of P1-2A, consistent with previous results using the
vaccinia virus expression system [13]. Furthermore, similar results were obtained using the var-
ious rSFV vectors in pBTY (bovine) and IBRS-2 (porcine) cells (see S1 Fig).
Assembly of FMDV empty capsids expressed by rSFV-FMDVs
The processed products of P1-2A can assemble into empty capsid particles (which sediment at
ca. 80S) and have much higher immunogenicity than the unprocessed P1-2A or unassembled
pentamers [7,39,40]. In order to assess the assembly of the products expressed from the
rSFV-FMDVs, infected cell lysates were analysed on sucrose gradients and the presence of
FMDV proteins, as detected by ELISA, in each gradient fraction was determined (Fig 4A). The
intact P1-2A remains close to the top of the gradient (mainly fractions 2–5) whereas the 3Cpro
processed products (expressed from the P1-2A3CC142S and P1-2A-mIRES-3C cassettes)
migrate much further into the gradient (in fractions 14 and 15) consistent with assembly into
empty capsid particles. Processed proteins that assembled into pentamers, an assembly inter-
mediate, migrate in an intermediate position (around fraction 7).
Fig 3. Characterization of expressed FMDV capsid proteins. (A) Uninfected BHK cells (control, lane 1) or cells
infected with rSFV (lane 2), rSFV-FMDV-P1-2A (lane 3), rSFV-FMDV-P1-2A-3CC142S (lane 4) or rSFV-FMDV-P1-2A-
mIRES-3C (lane 5) were harvested and the cell lysates were fractionated by SDS–PAGE. The proteins were transferred
to PVDFmembrane and probed with antibodies specific for FMDV capsid proteins (top), FMDV 2A (second), FMDV 3Cpro
(third) and β-actin (bottom) as indicated. Detection of β-actin was used as a control for equal protein loading. The results
shown are representative of three independent experiments. Molecular mass markers (kDa) are indicated on the left. (B)
Cell lysates, as used in panel A, were diluted (10-fold initially and then 2-fold dilutions) and analysed with a FMDV
serotype O-specific antigen ELISAs. The results shown are representative of two independent experiments. AU,
absorbance units.
doi:10.1371/journal.pone.0157435.g003
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The ability of the FMDV capsid proteins to bind specifically to the integrin αvβ6 (a cellular
receptor for FMDV) was also assessed using an ELISA (Fig 4B). The protomers, pentamers and
empty capsids were each able to bind specifically to this integrin in a divalent cation dependent
manner (binding was blocked in the presence of EDTA).
Vaccination of cattle with rSFV-FMDVs (animal experiment 1)
As an initial assessment of the ability of the single-cycle rSFV-FMDV vectors to induce a pro-
tective anti-FMDV response in a natural host, cattle were vaccinated with ca. 5 x 108 infectious
doses of either the rSFV-FMDV-P1-2A (group 2) or rSFV-FMDV-P1-2A-mIRES-3C (group
3) or mock-vaccinated with PBS (group 1). After 21 days, the animals were challenged with
FMDV O1/UKG 2001 (ca. 106 TCID50) by tongue inoculation. The vaccination with the
rSFV-FMDVs induced no change in body temperature and it was only after challenge with
FMDV that fever was induced (especially on PVD 22) (Fig 5A). There was no apparent differ-
ence in the appearance of clinical signs of FMD in the control animals (group 1) or the
Fig 4. Assembly and properties of FMDV protomers, pentamers and empty capsids expressed from
rSFV vectors. (A) BHK cells were infected as described in Fig 2 using the indicated rSFV-FMDVs.
Cytoplasmic extracts were prepared (16 h post infection) and sedimented through sucrose gradients (10–
30%) and fractionated. FMDV proteins from each fraction were detected using a serotype-specific antigen
ELISA. The location of protomers, pentamers and empty capsids are indicated. (B) Fractions (fr) from the
rSFV-FMDV-P1-2A-mIRES-3C infected BHK cells containing protomers (fr. 3), pentamers (fr. 7) and empty
capsids (fr. 15) were assayed to detect FMDV antigen binding, in the presence or absence of EDTA as
indicated, to the integrin αvβ6 coated directly onto plates. Binding buffer was used as the control. Results are
presented as mean ± SEM of triplicate samples.
doi:10.1371/journal.pone.0157435.g004
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vaccinated animals. All showed typical signs of FMDV infection including elevated body tem-
perature (Fig 5A), excess salivation and mouth lesions away from the site of inoculation (see
fuller description of clinical signs associated with FMDV infection below).
Although protection against FMDV challenge was not achieved in this initial experiment,
analysis of the sera (by ELISA) indicated that an anti-FMDV response was induced in the ani-
mals that received the rSFV-FMDV-P1-2A and the rSFV-FMDV-P1-2A-mIRES-3C. These
responses appeared strongest at PVD 14 but then either remained constant or declined (Fig
5B). Following challenge on PVD 21, there was a boost in the anti-FMDV response, as mea-
sured by the ELISA, that was apparent from PVD 24 or 25 in all animals and this was main-
tained until termination of the experiment on PVD 30. The unvaccinated animals also
Fig 5. Vaccination of cattle with rSFV-FMDV particles and response to FMDV challenge. The indicated animals (in experiment 1) were
unvaccinated (controls, C1, C2) or vaccinated on post-vaccination day (PVD) 0 with either the rSFV-FMDV-P1-2A (calves C3-C5) or the
rSFV-FMDV-P1-2A-mIRES-3C (calves C6-C8) vectors (indicated by vertical dotted line, marked rSFV) and challenged with FMDV on PVD 21
(indicated by vertical line, marked FMDV). (A) Body (rectal) temperatures in each animal were monitored on a daily basis. (B) Serum samples
collected at each indicated day were assayed for anti-FMDV antibodies in a serotype O-specific blocking ELISA. The diagnostic cut-off level (50%) in
the ELISA is indicated by the horizontal line. (C) The number of FMDVRNA copies present in the serum was determined by RT-qPCRs by reference
to a dilution series of a known concentration of FMDVRNA. The results are presented as copies of FMDV RNA/ml of serum. A level of 107 copies/ml
is indicated by a horizontal line.
doi:10.1371/journal.pone.0157435.g005
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seroconverted against FMDV by PVD 27 following challenge. Titration of the sera (initially
screened at 1:5 dilution) indicated that the level of anti-FMDV antibodies induced by the
rSFV-FMDVs alone was fairly modest (only up to a titre of 1:10). However, the initial vaccination
with the rSFV-FMDVs strongly enhanced the level of anti-FMDV antibodies (titres of 1:320 and
above) that could be detected, post-challenge, on PVD 27 and 30 (see Table 1). This suggested
that these vectors had primed the anti-FMDV immune response. In contrast, in the unvaccinated
animals, the titre of anti-FMDV antibodies was only 1:20 post-challenge (Table 1).
Detection of FMDV RNA in the cattle sera by RT-qPCR (Fig 5C), identified the presence of
the FMDV derived RNA on PVD 1 circulating in all 3 inoculated animals in group 3 (this was
maintained in 2 of the animals on PVD 2 as well). The assay detects sequences within the FMDV
IRES that is present within the rSFV-FMDV-P1-2A-mIRES-3C particles and thus indicates that
short term, low level (ca. 103 copies/ml), circulation of the packaged rSFV-FMDV RNA occurred
following vaccination. Since no IRES sequences are present in the rSFV-FMDV-P1-2A then no
signal for FMDV RNA could be expected to be observed in the sera from group 2 prior to chal-
lenge and this was indeed the result (Fig 5C). The presence of high levels of FMDV RNA was
detected in the serum of all animals following tongue inoculation with the infectious FMDV on
PVD 21. Viremia was apparent on PVD 22–24 in group 3 and from PVD 22 to PVD 25 in group
2 and extended through to PVD 27 in the control animals in group 1 (Fig 5C). The highest levels
of viral RNA were observed in the sera from control animals (up to 5.3 x109 RNA copies/ml in
calf C1 and 2.4 x 109 copies/ml in calf C2) while the peak level of viremia in animals that had
received the rSFV-FMDV-P1-2A-mIRES-3C were rather lower. In calf C6, the peak level of
FMDV RNA in serum was ca. 2.9 x 107 RNA copies/ml while 4 x 108 copies/ml observed in
calves C7 and C8 (calves C6-C8 are each in group 3). The profile of viremia in group 2 (that
received the rSFV-FMDV-P1-2A) was very similar to the control animals. With this small sam-
ple size, the significance of these differences in viremia (ca.10-100-fold reduction in peak levels)
in the group 3 animals is not certain but a trend of shorter duration and a lower level of viremia
in the rSFV-FMDV-P1-2A-mIRES-3C vaccinated cattle seems consistent.
Booster vaccination and contact challenge (animal experiment 2)
In an attempt to enhance the level of anti-FMDV antibodies prior to challenge, a second exper-
iment was performed in which a second vaccination with the rSFV-FMDV was given prior to
exposure of the animals to FMDV. In addition, two alternative challenge routes were used;
Table 1. Reciprocal titres of anti-FMDV antibodies (serotype O) in sera from unvaccinated and rSFV-FMDV vaccinated calves in experiment 1.
Pre-challenge Post-challenge
Group Vaccination and challenge Animal PVD 14 PVD 21 PVD 27 PVD 30
1 No vaccination (control) C1 - - - 20
Needle challenge C2 - - - 20
2 rSFV-FMDV-P1-2A C3 - - 320 320
Needle challenge C4 - - 320 320
C5 - 5 640 320
3 rSFV-FMDV-P1-2A-mIRES-3C C6 5 10 320 320
Needle challenge C7
C8
Calves C3 to C8 were vaccinated with the indicated rSFV-FMDV on PVD 0 and then challenged with FMDV by needle inoculation on PVD 21. To
determine the titre, sera collected from calves on PVD 14, 21, 27 and 30 were assayed in the ELISA using 2-fold dilutions starting at 1:5.—indicates
negative.
doi:10.1371/journal.pone.0157435.t001
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these were either direct needle inoculation of virus into the tongue, as in the first experiment,
or a contact challenge by exposure to FMDV infected calves. In this experiment, calves C1-C4
were unvaccinated while calves C5-C13 were each vaccinated with the rSFV-FMDV-P1-2A-
mIRES-3C (7.5 x 108 infectious units) on PVD 0 and then again on PVD 14. On PVD 28, the
control calves C1 and C2 plus the vaccinated calves C5-C7 were challenged with FMDV O
UKG 34/2001 (ca. 106 TCID50) into the tongue (as above). The inoculated calves C1 and C2
were then kept in contact with the naïve calves C3 and C4 plus the vaccinated calves C11 to
C13 in one stable (to determine if transmission could occur). Meanwhile, the calves C5 to C7
were kept in contact with calves C8 to C10 in a separate stable to assess whether transmission
of FMDV from the vaccinated and then needle-challenged animals to vaccinated animals
occurred.
The body temperatures of all cattle remained very constant (following primary and second-
ary vaccination) until after challenge with FMDV (representative data is shown in the S2 Fig,
panels A and B). In the animals that were directly challenged with FMDV on PVD 28, fever
became apparent in both the control (C1, C2) and vaccinated animals (C5-C7) on PVD 29 and
30 (S2 Fig, panels A and B). Fever was also observed (during the period PVD 31 to 36) in the
animals kept in contact (from PVD 29) with the challenged animals (data not shown). Typical
clinical signs of FMD were also observed during this period in all animals as in experiment 1
(data not shown).
In the blocking ELISA (using 1:5 dilution of sera, see S2 Fig, panels C and D), it was appar-
ent that animals (C5-C7) which received the rSFV-FMDV-P1-2A-mIRES-3C vector serocon-
verted against FMDV (by 7 or 14 days when next sampled) following the primary vaccination.
There was no apparent increase in the response following the second vaccination on PVD 14
but the presence of anti-FMDV antibodies was maintained. Following challenge with FMDV,
the level of anti-FMDV antibody increased to some degree in both the FMDV inoculated ani-
mals (C5 to C7 by PVD 34, see S2 Fig, panel D) and in the contact challenged animals (C8-C13
by PVD 37). However, these assays are only semi-quantitative and the results of the titrations
are more informative (see below). In the non-vaccinated animals, no anti-FMDV antibodies
could be detected prior to challenge but the FMDV-inoculated calves seroconverted by PVD
34 (S2 Fig, panel C) while the in-contact animals seroconverted by PVD 37.
Selected sera, based on the results from the screening ELISA, were titrated (see Table 2). At
PVD 14, fairly low antibody titres (1:5 to 1:40) were present in 7 of the 9 animals vaccinated
with the rSFV-FMDV-P1-2A-mIRES-3C and by PVD 28 (14 days after the second vaccination)
all 9 animals were seropositive but the antibody titres were still in the range of 1:5 to 1:40. Fol-
lowing FMDV challenge, on PVD 28 (by inoculation) or PVD 29 (by contact), there was a
large rise in the level of antibodies to FMDV in the vaccinated animals (frequently to titres of
1:1280 or higher, see Table 2). In contrast, in the non-vaccinated animals (groups 1 and 2), the
post-challenge titres only reached 1:20 or 1:40. Thus, as in experiment 1, the inoculation with
the rSFV-FMDV-P1-2A-mIRES-3C strongly primed the anti-FMDV antibody response that
was generated post-challenge.
The presence of FMDV RNA in the cattle serum was determined by RT-qPCR. As in the
first experiment, the primary vaccinations of the cattle with the rSFV-FMDV-P1-2A-mIRES-
3C resulted in a weak signal, corresponding to the presence of the FMDV IRES in this recombi-
nant virus, on PVD 1 and, in some cases on PVD 2 (see S2 Fig, panel F). However, no such sig-
nal was detected in the sera following the second vaccination, with the same material, on
PVD14. Following challenge with FMDV, a large increase in viremia (as judged by the level of
FMDV RNA in the serum) was apparent in all animals but, consistent with the first experi-
ment, the level of viremia was greatly reduced (up to 1000-fold) in the vaccinated animals com-
pared to the control animals (S2 Fig, panels E and F). It is apparent that the vaccinated and
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then FMDV-challenged animals (group 3) were still able to transmit the virus to other vacci-
nated animals (group 4, see Table 2) as they became infected. Indeed, all animals showed typi-
cal clinical disease following challenge.
A prime-boost vaccination strategy prevents FMDV circulation and
disease (animal experiment 3)
To determine if the use of a prime-boost strategy, using two different types of vaccine would be
effective in combating virus replication, a third experiment was performed in which the combi-
nation of the rSFV-FMDV single-cycle virus infection and administration of purified recombi-
nant FMDV empty capsid particles was tested. Animals in group 1 (C1-C3) were
unvaccinated. Animals in group 2 (C4-C6) were vaccinated with rSFV-FMDV-P1-2A-mIRES-
3C on PVD 0 and then boosted with FMDV empty capsids on PVD 14. The calves in group 3
(C7-C9) were given the same components but in the reverse order. All the animals in each
group were challenged with FMDV on PVD 28 by needle inoculation.
a) Clinical signs of FMDV-infection post-challenge. No body temperature changes were
observed during the first 28 days of the experiment, prior to challenge (Fig 6A–6C). However,
the calves in groups 1 and 3 showed a marked body temperature increase for at least 3 days
post challenge with FMDV (Fig 6A and 6C) but only a small temperature response was
detected in each of the animals in group 2 (Fig 6B) indicative of some local response at the site
of virus inoculation.
In the unvaccinated group (control), all 3 animals (C1- C3) showed clinical signs consistent
with FMDV infection after challenge. The day after needle challenge (PVD 29), the animals
showed excess salivation and were reluctant to eat food but no lesions were observable by
inspection of the mouth cavity. On the following day (PVD 30), lesions at the inoculation sites
were visible. Furthermore, at PVD 31 and 32, several lesions were observed in the mouth cavity
and included secondary sites on the tongue, the dorsal palate and the gingiva. At PVD 33, the
animals showed increased interest in food again and at PVD 35 all lesions had started healing.
Table 2. Reciprocal titres of anti-FMDV antibodies (serotype O) in sera from unvaccinated and rSFV-FMDV vaccinated calves in experiment 2.
Pre-challenge Post-challenge
Group Vaccination and challenge Animal PVD 14 PVD 28 PVD 42
1 No vaccination (control) C1 - - 40
Needle challenge C2 - - 40
2 No vaccination (control) C3 - - 20
Contact challenge from group 1 C4 - - 20
3 rSFV-FMDV-P1-2A-mIRES-3C x 2 C5 5 20 1280
Needle challenge C6 20 40 2560
C7 40 20 640
4 rSFV-FMDV-P1-2A-mIRES-3C x 2 C8 - 5 640
Contact challenge from group 3 C9 - 5 320
C10 20 40 1280
5 rSFV-FMDV-P1-2A-mIRES-3C x 2 C11 40 20 2560
Contact challenge from group 1 C12 5 5 2560
C13 5 5 1280
Calves C5 to C13 were vaccinated with rSFV-P1-2A-mIRES-3C on PVD 0 and also on PVD 14 and then challenged with FMDV by needle inoculation on
PVD 28 (groups 1 and 3) or by contact with inoculated calves from PVD 29 (groups 2, 4 and 5, see text). To determine the antibody titres, sera collected
from calves on PVD 14, 28 and 42 were assayed in the ELISA using 2-fold dilutions starting at 1:5.—indicates negative.
doi:10.1371/journal.pone.0157435.t002
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In general, excess salivation and decreased appetite were the most consistent clinical signs dur-
ing the experimental period after FMDV challenge.
In group 2, each of the calves, C4-C6, that had been vaccinated with the rSFV-FMDV-P1-
2A-mIRES-3C and then boosted with the empty FMDV capsid particles, showed some saliva-
tion from PVD 29 (visually to a lesser degree than calves in the control group), lesions were
observed on the tongues at the FMDV inoculation sites from PVD30. However, no other
lesions were seen. From PVD 32, the lesions at the sites of inoculation began to heal and by the
end of the experiment the epithelia on the tongues of these cattle were intact. In general, sparse
salivation and normal appetite were observed during the experimental period after FMDV
challenge.
Fig 6. Prime-boost vaccination strategy effectively induces anti-FMDV antibodies in cattle and blocks virus circulation post-challenge. In
experiment 3, calves in group 1 (panels A, D, G) were unvaccinated. Calves in group 2 (panels B, E, H) were vaccinated with rSFV-FMDV-P1-2A-
mIRES-3C on PVD 0 (dotted vertical line, marked rSFV) and then with O1 Manisa empty capsid particles on PVD 14 (dotted vertical line, marked
ECs). Calves in group 3 (panels C, F, I) were vaccinated with O1 Manisa empty capsid particles on PVD 0 (dotted vertical line, marked ECs) and
then with rSFV-FMDV-P1-2A-mIRES-3C on PVD 14 (dotted vertical line, marked rSFV). All animals were challenged with FMDV (O UKG/34/2001)
on PVD 28 (indicated by solid vertical line, marked FMDV). Body temperatures in each animal were monitored on a daily basis (panels A-C). Sera
were collected from each calf on the indicated days and assayed in the serotype O blocking ELISA (panels D-F). Results are presented as ODP (%)
with a cut-off value of 50% (indicated by horizontal line). The presence of FMDV RNA circulating in serum was assayed by RT-qPCR (panels G-I).
The results are presented as copies of FMDVRNA/ml of serum as in Fig 5. A level of 107 copies/ml is indicated by a horizontal line.
doi:10.1371/journal.pone.0157435.g006
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All 3 animals (C7-C9) in group 3 (which received the empty capsids followed by the
rSFV-FMDV-P1-2A-mIRES-3C) showed increased salivation from PVD 29. Lesions were
observed at the inoculation sites from PVD 30 and one animal had an additional single lesion
in the mouth cavity behind the front teeth at this time. At PVD 31–32, extreme salivation was
recorded as well as several lesions in the oral cavity on the tongue and dorsal palate in the
calves. Furthermore, one calf had lesions on one foot (right hind limb) and one calf had a single
lesion in the left nostril. At PVD 34, the calves had improved in their general condition and
showed increased interest in food again. At PVD 35–36, the lesions had started to heal. In gen-
eral, massive salivation and decreased appetite (as for calves in group 1) were observed during
the experimental period after FMDV challenge.
At necropsy, after the termination of the experiment, healing lesions were observed on the
feet and around the mouth in groups 1 and 3. In group 2, a healing lesion at the base of the ton-
gue was observed in one animal only.
b) Induction of anti-FMDV antibodies. As expected, no anti-FMDV antibodies were
detected in unvaccinated cattle (C1-C3) prior to challenge (Fig 6D). For calves C4-C6 (group
2), initial vaccination (on PVD 0) with the rSFV-FMDV-P1-2A-mIRES-3C particles was fol-
lowed on PVD 14 with the serotype OManisa empty capsid particles (produced by a vaccinia
virus expression system). This antigen strongly boosted the anti-FMDV immune response
detected at PVD 21 and PVD 28 (Fig 6E) compared to that seen at PVD 14 and produced an
antibody titre of 1:40 to 1:320 (by ELISA) in all 3 animals (Table 3) at PVD 28. In group 3,
comprising calves C7-C9, initial vaccination with the empty capsid particles produced only a
relatively weak anti-FMDV response by PVD 14 but this was boosted, as determined at PVD
28, by the inoculation with the rSFV-FMDV-P1-2A-mIRES-3C but not to the same degree as
in group 2 (see Fig 6F and Table 3).
Following challenge with FMDV on PVD 28 there was only a moderate change in the level
of anti-FMDV antibodies in the animals in group 2 (Fig 6E and Table 3) to 1:320 or 1:1280.
There was a much stronger increase in the anti-FMDV immune response in group 3 (Fig 6F),
compared to group 2, following challenge (Table 3) with titres of 1:5120 reached in each ani-
mal. The control animals also seroconverted against FMDV following challenge (Fig 6D) but
the titres of antibodies were much lower (1:40 or 1:160) (Table 3).
Table 3. Reciprocal titres of anti-FMDV antibodies (serotype O) in sera from calves in experiment 3.
Post-prime Post-boost Post-challenge
Group Vaccination Animal PVD 14 PVD 28 PVD 36
1 No vaccination (control) C1
C2
C3
2 rSFV-FMDV-P1-2A-mIRES-3C C4
(PVD 0) + empty capsid particles C5
(PVD 14) C6
3 empty capsid particles (PVD 0) + C7
rSFV-FMDV-P1-2A-mIRES-3C C8
(PVD 14) C9
Calves were either unvaccinated (group 1) or vaccinated with rSFV-FMDV-P1-2A-mIRES-3C (on PVD 0) followed by empty capsid particles (on PVD 14)
(group 2) or vaccinated with empty capsids on PVD 0 and then with rSFV-FMDV-P1-2A-mIRES-3C on PVD 14 (group 3). All cattle were challenged with
FMDV by needle inoculation on PVD 28. Sera collected on PVD 14, 28 (pre-challenge) and 36 were titred in the blocking ELISA using 2-fold dilutions
starting at 1:5.—indicates negative.
doi:10.1371/journal.pone.0157435.t003
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c) Post-challenge viremia. In the control animals (C1-C3), high levels of viremia (as
determined by RT-qPCR) could be detected in the sera following FMDV challenge (see Fig 6G)
which lasted for 3 days, this was largely coincident with the elevated temperature response (Fig
6A). In contrast, there was a complete block on viremia in group 2 post challenge; no FMDV
RNA could be detected in the sera from calves C4-C6 following inoculation with FMDV (Fig
6H). The complete lack of viremia was consistent with the absence of disease in the animals in
this group. In group 3, a marked viremia was observed in one animal (C9), which lasted for 2
days (Fig 6I). In addition, a much lower level of FMDV RNA was detected in the serum of calf
C7 for a period of 3 days. In the third calf (C8), only a very low viremia was detected, on a sin-
gle day; this result is consistent with the fact that this calf had the highest level of anti-FMDV
antibodies, within this group (see Fig 6F, Table 3), on PVD 28 (pre-challenge).
d) Induction of neutralizing antibodies. Neutralizing antibodies in selected serum sam-
ples were also measured using VNTs (Fig 7A–7C). These assays indicated that strong anti-
FMDV neutralizing antibody responses were generated by the prime-boost strategy used in
animals C4-C6 by PVD 28 and that the use of the same components, in the opposite order in
animals C7-C9, was much less efficient (Fig 7B). Interestingly, the level of neutralizing antibod-
ies induced by the FMDV challenge in the naïve animals (C1-C3, see Fig 7C) was not very dif-
ferent from that observed pre-challenge (PVD 28) in calves C4-C6 (rSFV-FMDV-primed and
empty capsid-boosted). In calves C4-C6, there was little change in the level of neutralizing anti-
bodies post-challenge (c.f. Fig 7B and 7C). In contrast, in calves C7-C9, there was a large
increase in the level of neutralizing antibodies post-challenge (c.f. Fig 7B and 7C) consistent
with the apparent FMDV infection.
Discussion
Current vaccines to prevent FMD rely on the production of large quantities of infectious
FMDV that are then chemically inactivated and injected, with an adjuvant, to induce protec-
tion against disease [7,8]. These vaccines have proved effective in controlling the disease in
Europe but the disease is still endemic in many countries around the world, especially within
Africa and parts of Asia. There are multiple, significant shortcomings with current FMD vac-
cines (see [9]) and hence there is a need to develop improved systems to allow better control of
the disease. The focus here has been to express, within the cytoplasm, RNAs encoding the
FMDV proteins required for the formation of empty capsid particles. It has been established
that expression of the capsid precursor P1-2A along with a relatively low level of the 3Cpro (c.f.
the viral polyprotein that yields equimolar amounts of the capsid precursor and 3Cpro) is opti-
mal to achieve efficient production of the FMDV empty capsid components [11,12,13,26] that
can form the basis of improved vaccines.
The split-helper SFV vector system [23] generates virus particles that are able to initiate
only a single round of virus infection. SFV replicates entirely within the cytoplasm of cells and
produces a sub-genomic RNA that can be modified to express foreign antigens. In this study,
rSFVs have been constructed to express the O1 Manisa FMDV capsid precursor (P1-2A) alone
or with the FMDV 3Cpro (see Fig 1). The FMDV products had the expected physical properties
and were able to bind both to FMDV antibodies and to the cellular receptor for FMDV (see
Figs 3 and 4). Assembly of the processed viral proteins into rapidly sedimenting particles, con-
sistent with the formation of empty capsid particles, was also demonstrated (Fig 4A).
It is known that serotype A FMDVs frequently generate empty capsid particles at a high
level within FMDV-infected cells whereas the serotype O FMDVs do not normally show this
property [10,39]. This may reflect differences in the stability of these particles and may contrib-
ute to the better success with the adenovirus vectors that express serotype A rather than
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Fig 7. Production of neutralizing anti-FMDV antibodies in cattle. Sera from the calves in group 1 (C1-C3,
black bars, control), group 2 (C4-C6, red bars, vaccinated with rSFV-FMDV-P1-2A-mIRES-3C on PVD 0
followed by empty capsids on PVD 14) and group 3 (C7-C9, blue bars, vaccinated with empty capsids on
PVD 0 followed by rSFV-FMDV-P1-2A-mIRES-3C on PVD 14) were collected during the experiment 3. All
animals were challenged with FMDV on PVD 28. Samples from PVD 14 (A), PVD 28 (B) (prior to challenge)
and PVD 36 (C) (post challenge) were assayed for the presence of neutralizing anti-FMDV antibodies using
VNTs. Results were calculated as reciprocal VNT titres and are displayed as log2 values. VNT titres 11
(log2 11 = 3.459) are considered negative while titres45 (log2 45 = 5.492) are considered positive.
Intermediate titres are considered as inconclusive (indicated within grey bar).
doi:10.1371/journal.pone.0157435.g007
Prime-Boost Vaccination to Block FMD
PLOSONE | DOI:10.1371/journal.pone.0157435 June 13, 2016 18 / 23
serotype O capsid sequences [21]. The O1 Manisa strain, as used here, has been extensively
employed for vaccine production and may be better in this respect than many other serotype O
viruses [13].
Single cycle rSFV vectors that express the O1 Manisa capsid protein precursor alone and
also with the 3Cpro have now been produced and characterized. Following a single inoculation
of the rSFVs into cattle, the major target species for vaccination against FMD, an anti-FMDV
response was induced but the level of antibodies produced was relatively low and proved insuf-
ficient to protect against challenge with a serotype O FMDV (into the tongue). However, the
prior vaccination, with the rSFV-FMDV-P1-2A-mIRES-3C appeared to reduce the duration
and level of viremia that occurred following the FMDV challenge. More significantly, it was
also noted that a much higher level of anti-FMDV antibodies was generated, post-challenge, in
the vaccinated animals than in the naïve controls (Table 1). This suggested that the rSFVs had
primed the host immune response against the FMDV infection. This effect was observed in
animals inoculated with the rSFV-FMDV-P1-2A and also, separately, with the
rSFV-FMDV-P1-2A-mIRES-3C but the reduction in FMDV RNA in the serum was clearest
with the rSFV-FMDV-P1-2A-mIRES-3C.
In a second experiment, which focused on the use of the rSFV-FMDV-P1-2A-mIRES-3C, it
was found that a second vaccination with the same recombinant virus did not significantly
improve the host immune response against FMDV (see S2 Fig and Table 2). It may be that the
host response to the SFV particles induced by the primary vaccination blocked the ability of
the rSFV to boost the anti-FMDV response. Indeed, the rSFV-FMDV-P1-2A-mIRES-3C was
not detected (by RT-qPCR) in the serum of any of the animals following the 2nd vaccination,
while it was detected in nearly all animals following the primary inoculation (see Fig 5C and S2
Fig). These twice-vaccinated animals were not protected against FMDV infection, neither from
direct inoculation (S2 Fig) nor by a more natural route of infection from another infected ani-
mal. However, once again a strong priming response was apparent from the anti-FMDV anti-
body titres (Table 2). These results suggested the potential utility of performing a two-stage
vaccination process using the rSFV-FMDV in conjunction with purified FMDV empty capsid
particles produced by another viral vector (as in [10,11]). The encapsidated rSFV-FMDV vec-
tor is technically fairly complex to produce and should be considered as a “proof of principle”
for developing a cytoplasmic RNA vector based system for the expression of FMDV empty cap-
sid particles within cells.
We have now shown that administration of the FMDV empty capsid particles after the
initial vaccination with the rSFV-FMDV particles gave rise to a high level of anti-FMDV anti-
bodies, prior to challenge. This immune response completely suppressed disease and the circu-
lation of the virus in serum in all 3 calves (C4-C6) (see Fig 6H) and no lesions were observed
away from the site of inoculation. It is noteworthy that the order of the inoculations is very
important; the administration of the FMDV empty capsids followed by the rSFV-FMDV gave
a much less effective immune response, pre-challenge, than the reverse order (Fig 6F and
Table 3). The levels of circulating anti-FMDV antibodies were lower pre-challenge in all 3
calves (C7-C9) and significant viremia was detected post-challenge (although much lower
than in unvaccinated animals) (Fig 6I). Furthermore, a much greater enhancement of anti-
FMDV antibody levels was seen post-challenge (up to a titre of 1:5120) in group 3 compared to
group 2 animals (see Table 3), presumably reflecting this higher level of FMDV replication.
Similarly, the anti-FMDV titres measured by VNT greatly increased post-challenge in calves
C7-C9 and also in the control group (calves C1-C3) but hardly changed in calves C4-C6
(Fig 7B and 7C).
It has been reported in an earlier study, that in cattle given two vaccinations with wt A22
empty capsid particles alone and then challenged with FMDV, all 4 animals showed viremia on
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at least one day [11]. Furthermore, 2 of 4 animals given two vaccinations with stabilized A22
empty capsids also showed viremia on 1 day post challenge. In the current study, in total some
30 cattle have been challenged with FMDV; viremia plus disease was observed in each of them
except for the group that had received the prime-boost vaccination strategy employing the
rSFV-FMDV-P1-2A-mIRES-3C followed by the empty capsid particles. The latter animals
showed no disease; they had a complete absence of viremia and no spread of the virus from the
site of inoculation was apparent.
It is noteworthy that current FMDV vaccines, although conferring protection against dis-
ease, do not provide sterile immunity [41]; indeed vaccinated and sub-clinically infected cattle
are able to transmit the virus to other susceptible animals [42]. Future studies should address
whether cattle, which have been vaccinated using the prime-boost strategy described here, are
still able transmit the disease following virus challenge. Furthermore, it will also be important
to determine the duration of the protective immune response generated by such vaccination
regimes. An assessment of the role of the rSFV-FMDV in inducing cell-mediated immune
responses will be a component of such studies. As indicated above, current control strategies
can require vaccination 2–3 times per year since the duration of protection is rather limited. It
is envisaged that any further boost of the immune response that may be required, following the
prime-boost vaccination described here, could employ just the empty capsid particles and not
require further priming with the rSFV-FMDV but this remains to be determined.
Both components of the prime-boost strategy described here can be produced outside of
high-containment facilities and the system should be applicable to each of the FMDV sero-
types. In addition, there is no requirement to adapt a particular FMDV strain for growth in cell
culture to allow vaccine production.
Supporting Information
S1 Fig. Detection of expressed FMDV capsid proteins in bovine and porcine cells. Primary
bovine thyroid cells (pBTY) (panels A and C) or porcine IBRS-2 cells (panels B and D) were
infected with the indicated rSFVs. Cell lysates were prepared and analysed using SDS–PAGE
and immunoblotting. The membranes were probed with antibodies specific for FMDV capsid
proteins (panels A and B, top) and β-actin (panels A and B, bottom). Detection of β-actin was
used as a control for equal protein loading. The results shown are representative of three inde-
pendent experiments. Molecular mass markers (kDa) are indicated on the left. Cytoplasmic
extracts were also analysed using an FMDV antigen ELISA (as in Fig 3). Cell lysates, (as used
for panels A and B) were diluted (10-fold initially and then 2-fold dilutions) and analysed
using an FMDV serotype O-specific antigen ELISA. The results shown are representative of
two independent experiments. AU, absorbance units.
(TIF)
S2 Fig. Effect of primary and secondary vaccination of cattle with rSFV-FMDV-P1-2A-
mIRES-3C. In experiment 2, calves in group 1 (C1 and C2, see panels A, C and E) were unvac-
cinated. The animals in group 3 (C5-C7, see panels B, D, and F) were vaccinated with
rSFV-FMDV-P1-2A-mIRES-3C on PVD 0 and again on PVD 14. The calves in groups 1 and 3
were challenged with FMDV by needle inoculation on PVD 28. Rectal temperatures were
recorded on a daily basis. (see panels A, B) Serum was collected from each animal on the indi-
cated days and assayed for anti-FMDV antibodies by blocking ELISA. The diagnostic cut-off
level (50%) in the assay is indicated (see panels C, D). FMDV RNA in the sera from the indi-
cated calves was measured by RT-qPCR and presented as RNA copies/ml as in Fig 5. A level of
107 copies/ml is indicated by a horizontal line (see panels E, F).
(TIF)
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